NCT00763555 - Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

March 31, 2009

Conditions

Psoriasis

Interventions

DRUG

CD 2027

Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.

DRUG

Calcitriol Vehicle

Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.

Trial Locations (6)

Tennessee Clinical Research Center, Nashville

Minnesota Clinical Study Center, Fridley

Stratica Medical, Edmonton

Ultranova Skincare, Barrie

North Bay Dermatology Centre, North Bay

K. Papp Clinical Research, Inc., Waterloo